NASDAQ:LJPC La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free LJPC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$3.12▼$6.2252-Week Range N/AVolume66,708 shsAverage Volume158,476 shsMarket Capitalization$155.11 millionP/E Ratio51.84Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get La Jolla Pharmaceutical alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About La Jolla Pharmaceutical Stock (NASDAQ:LJPC)La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. LJPC Stock News HeadlinesMarch 27, 2024 | msn.comLa Jolla small business owners want lawful path to conduct business on the beachDecember 19, 2023 | health.usnews.comScripps Green HospitalMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.September 25, 2023 | fool.comLa Jolla Pharmaceutical (NASDAQ: LJPC)July 27, 2023 | finance.yahoo.comHepatorenal Syndrome Treatment Global Market Report 2023May 16, 2023 | marketwatch.comThalassemia Market Research | 2023-2030May 11, 2023 | businesswire.comResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet ...May 10, 2023 | marketwatch.comKidney (Renal) Fibrosis Market Report | Research Across The World 2031May 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.May 8, 2023 | marketwatch.comKidney Fibrosis Treatment Market Dynamics and Drivers: 2023-2031May 5, 2023 | marketwatch.comBased on recent market research, the Kidney/Renal Fibrosis Treatment market is set to experience robust growth, with a CAGR of 7% from 2023 to 2030.May 4, 2023 | marketwatch.comFibrodysplasia Ossificans Progressiva Drug Market Historical Trends and Future Prospect till 2031May 3, 2023 | usnews.comLa Jolla High SchoolApril 19, 2023 | markets.businessinsider.comCan The Proposed Antibiotic For Multidrug-Resistant Infections Fuel Innoviva's Revenue Growth?April 8, 2023 | marketwatch.comThalassemia Market Complete Overview till 2030April 7, 2023 | marketwatch.comKidney Fibrosis Treatment Market-An Exclusive Study On Upcoming Trends And Growth Opportunities From 2023-2030April 6, 2023 | marketwatch.comKidney/Renal Fibrosis Treatment Market Size By 2031March 27, 2023 | marketwatch.comGlobal Thalassemia Market Size 2023 to 2026 Size and Share Survey ReportMarch 22, 2023 | marketwatch.comKidney Fibrosis Treatment Market Major Players, Anlysis and Forecast till 2031March 20, 2023 | marketwatch.comKidney/Renal Fibrosis Treatment Market Analysis 2023-2028, Newly Upgraded ReportMarch 18, 2023 | health.usnews.comScripps La Jolla HospitalsMarch 17, 2023 | marketwatch.comFibrodysplasia Ossificans Progressiva Drug Market Share, Segmentation and Forecast 2023-2028March 17, 2023 | marketwatch.comGlobal Fibrodysplasia Ossificans Progressiva Drug Market Size by Application (Hospital, Clinic, Research Center) Forecast from 2023 to 2028March 15, 2023 | marketwatch.comHeavy Metal Poisoning Drugs Market Size 2023 Research Report by Growth Rate Analysis and Forecast till 2027March 13, 2023 | marketwatch.comFibrodysplasia Ossificans Progressiva Drug Market Research Report 2023-2028 with Top Countries DataMarch 12, 2023 | marketwatch.comGlobal Thalassemia Market Growth Prospects, Geography, Drivers, and Restraints 2023 – 2030 By VMReportsMarch 10, 2023 | marketwatch.comKidney (Renal) Fibrosis Market Potential Analysis, by Trending Growth and CAGR 2023 to 2028See More Headlines Receive LJPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2022Today5/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LJPC CUSIPN/A CIK920465 Webwww.lajollapharmaceutical.com Phone(617) 715-3600Fax858-626-2851Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.12 Trailing P/E Ratio51.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$19.66 million Net Margins8.54% Pretax Margin8.64% Return on Equity-5.46% Return on Assets4.00% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.52 Sales & Book Value Annual Sales$75.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.95 Book Value($2.94) per share Price / BookN/AMiscellaneous Outstanding Shares24,937,000Free Float15,885,000Market Cap$155.11 million OptionableOptionable Beta2.39 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Larry G. Edwards (Age 50)Pres, CEO & Director Comp: $858.87kMr. Michael S. Hearne (Age 59)CFO & Sec. Comp: $207.38kMs. Paula RusuVP of OperationsMs. Sandra VedrickSr. Director of Investor Relations & HRMr. Luke Seikkula (Age 58)Sr. VP of Pharmaceutical Operations Dr. Lakhmir S. Chawla M.D. (Age 51)Consultant Mr. Stewart M. Kroll (Age 63)Chief Devel. Officer Mr. Mark D. WilliamsSr. VP of Medical AffairsMr. Tony N. Hodges FACPM.D., Chief Medical OfficerMore ExecutivesKey Competitors10X Capital Venture Acquisition Corp. IIINYSE:VCXBCompugenNASDAQ:CGENCellectisNASDAQ:CLLSScilexNASDAQ:SCLXKodiak SciencesNASDAQ:KODView All Competitors LJPC Stock Analysis - Frequently Asked Questions How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) issued its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.16. The biopharmaceutical company had revenue of $10.43 million for the quarter, compared to analyst estimates of $13.10 million. La Jolla Pharmaceutical had a negative trailing twelve-month return on equity of 5.46% and a net margin of 8.54%. What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO? 8 employees have rated La Jolla Pharmaceutical Chief Executive Officer George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among the company's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA). This page (NASDAQ:LJPC) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding La Jolla Pharmaceutical Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.